See more : Coronado Global Resources Inc. (CODQL) Income Statement Analysis – Financial Results
Complete financial analysis of Aadi Bioscience, Inc. (AADI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aadi Bioscience, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Renalytix Plc (RTNXF) Income Statement Analysis – Financial Results
- Texmaco Rail & Engineering Limited (TEXRAIL.NS) Income Statement Analysis – Financial Results
- Angel Pond Holdings Corporation (POND-WT) Income Statement Analysis – Financial Results
- ThinkSmart Limited (TSL.L) Income Statement Analysis – Financial Results
- Bell Food Group AG (0RFX.L) Income Statement Analysis – Financial Results
Aadi Bioscience, Inc. (AADI)
About Aadi Bioscience, Inc.
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 24.35M | 15.22M | 1.00M | 14.00M | 749.00K | 20.16M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 2.81M | 1.34M | 276.00K | 176.00K | 76.50K | 0.00 | 51.27K | 69.67K | 57.98K | 23.97K | 22.82K | 22.39K | 23.59K | 20.51K | 0.00 | 0.00 |
Gross Profit | 21.55M | 13.88M | 724.00K | 13.82M | 672.50K | 20.16M | -51.27K | -69.67K | -57.98K | -23.97K | -22.82K | -22.39K | -23.59K | -20.51K | 0.00 | 0.00 |
Gross Profit Ratio | 88.47% | 91.23% | 72.40% | 98.74% | 89.79% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 48.93M | 32.66M | 19.67M | 15.01M | 12.82M | 17.85M | 12.15M | 11.37M | 11.63M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 0.00 | 0.00 | 18.51M | 2.12M | 1.85M | 13.49M | 9.24M | 29.49K | 23.01K | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 7.83M | -46.69K | -51.27K | 5.17M | 5.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 44.55M | 40.18M | 18.51M | 2.12M | 9.68M | 13.44M | 9.19M | 5.20M | 5.80M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | 0.00 |
Other Expenses | 0.00 | 5.06M | -120.00K | -580.00K | -142.73K | -6.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -33.62K |
Operating Expenses | 93.48M | 72.84M | 38.06M | 16.55M | 22.50M | 31.29M | 21.34M | 16.56M | 17.43M | 22.82K | 22.39K | 23.59K | 20.51K | 20.51K | 0.00 | -33.62K |
Cost & Expenses | 96.29M | 74.17M | 38.06M | 16.55M | 22.58M | 31.34M | 21.39M | 16.63M | 17.49M | 22.82K | 22.39K | 23.59K | 20.51K | 41.02K | 0.00 | -33.62K |
Interest Income | 6.40M | 2.40M | 13.00K | 41.00K | 1.03M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 231.00K | 230.00K | 665.00K | 815.00K | 0.00 | 778.22K | -105.78K | 9.94K | 8.43K | 5.88K | 4.97K | 3.60K | 1.89K | 1.89K | 0.00 | 0.00 |
Depreciation & Amortization | 169.00K | 159.00K | 276.00K | 176.00K | 76.50K | 46.69K | 51.27K | 69.67K | 57.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA | -65.37M | -60.12M | -109.15M | -2.49M | -24.44M | -10.35M | -21.24M | -16.43M | -17.01M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
EBITDA Ratio | -268.40% | -371.71% | -3,546.30% | -18.94% | -3,004.55% | -55.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -71.93M | -58.96M | -111.22M | -2.55M | -22.58M | -11.18M | -21.39M | -16.63M | -17.49M | -22.82K | -22.39K | -23.59K | -20.51K | -41.02K | 0.00 | -33.62K |
Operating Income Ratio | -295.36% | -387.47% | -11,121.70% | -18.21% | -3,014.77% | -55.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 6.17M | 2.17M | 1.13M | -927.00K | 1.17M | 784.61K | -12.07K | -349.93K | 416.33K | 17.15K | 16.95K | 17.42K | 19.99K | 18.62K | 0.00 | 0.00 |
Income Before Tax | -65.77M | -60.51M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
Income Before Tax Ratio | -270.04% | -397.69% | -11,008.80% | -24.83% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 0.00 | -3.50M | 2.00K | 2.00K | 1.30K | 778.22K | -12.06K | -3.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | -65.77M | -57.01M | -110.09M | -3.48M | -23.27M | -10.40M | -21.40M | -16.98M | -17.07M | -28.70K | -27.37K | -27.19K | -22.40K | -22.40K | 0.00 | -33.62K |
Net Income Ratio | -270.04% | -374.67% | -11,009.00% | -24.84% | -3,106.88% | -51.58% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
EPS Diluted | -2.44 | -2.53 | -12.34 | -20.52 | -8.60 | -4.60 | -14.81 | -9.42 | -9.47 | -0.02 | -0.02 | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
Weighted Avg Shares Out | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Weighted Avg Shares Out (Dil) | 26.92M | 22.51M | 8.92M | 169.49K | 2.71M | 2.26M | 1.44M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 1.80M | 5.00M | 0.00 | 0.00 |
Aadi Bioscience, Inc. (AADI) Reports Q3 Loss, Tops Revenue Estimates
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update
Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Lags Revenue Estimates
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update
Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update
3 Russell 2000 Stocks to Sell in July Before They Crash & Burn
Aadi Bioscience to Participate in the Jefferies Healthcare Conference
Source: https://incomestatements.info
Category: Stock Reports